Literature DB >> 10640614

Intracerebral transportation and cellular localisation of insulin-like growth factor-1 following central administration to rats with hypoxic-ischemic brain injury.

J Guan1, E J Beilharz, S J Skinner, C E Williams, P D Gluckman.   

Abstract

Insulin-like growth factor-1 (IGF-1) has been shown to be neuroprotective when administered centrally following hypoxic-ischemic (HI) brain injury. However, the cerebral distribution and site of action of IGF-1 after intracerebroventricular (i.c.v.) administration are not known. A unilateral HI brain injury was induced in adult rats by a modified Levine method. Either 3H-IGF-1 alone, or in combination with unlabelled IGF-1, was administered into the lateral ventricle 2 h after injury. The activity of 3H-IGF-1 signal in the potentially injured cortex was compared between two treatment groups using image analysis. The regional distribution and cellular localisation of 3H-IGF-1 were examined autoradiographically in potentially injured hemispheres at 0.5 and 6 h after administration. Tritiated IGF-1 was detected predominantly in the pia mater, perivascular spaces and subcortical white matter tracts 0.5 h after administration and decreased by 6 h (p<0.05). The signals associated with the perivascular spaces and pia mater were not blocked by unlabelled IGF-1, suggesting non-saturable binding in these brain areas. IGF-1 signal was co-localised with IGF binding protein (IGFBP)-2 immunostaining in the white matter tracts where the signal was blocked by unlabelled IGF-1, suggesting competitive association. IGF-1 signal associated with neurons and glia was maximal in the cerebral cortex and less in the CA1-2 subregion of the hippocampus which were blocked by unlabelled IGF-1 (p<0.05). The signals from cortical neurons did not decrease 6 h after administration, suggesting specific and persistent binding to these cells. Our results indicate that centrally administered IGF-1 can be translocated to neurons and glia via the perivascular circulation and the ependymal cell-white matter tract pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640614     DOI: 10.1016/s0006-8993(99)02030-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 2.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Temporal and regional changes in IGF-1/IGF-1R signaling in the mouse brain after traumatic brain injury.

Authors:  Sindhu Kizhakke Madathil; Heather N Evans; Kathryn E Saatman
Journal:  J Neurotrauma       Date:  2010-01       Impact factor: 5.269

Review 4.  IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions.

Authors:  Jian Guan; Peter D Gluckman
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

5.  Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats.

Authors:  Silke Glage; Petra M Klinge; Miles C Miller; Christine Wallrapp; Peter Geigle; Hans J Hedrich; Thomas Brinker
Journal:  Fluids Barriers CNS       Date:  2011-05-17

6.  In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain.

Authors:  Tavarekere N Nagaraja; Padma Patel; Martin Gorski; Peter D Gorevic; Clifford S Patlak; Joseph D Fenstermacher
Journal:  Cerebrospinal Fluid Res       Date:  2005-07-26

7.  Effects of early administration of insulin-like growth factor-1 on cognitive function in septic encephalopathy.

Authors:  Yang Yang; Shengru Liang; Yuqian Li; Fei Gao; Yuan Cao; Xiaoyu Zhao; Guodong Gao; Lihong Li
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-23       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.